The United States Agency for International Development (USAID) and Janssen Therapeutics, have agreed to provide a newly developed tuberculosis drug for free to patients suffering from strains of TB that are resistant to two or more antibiotics.
Janssen will donate $30 million worth (30,000 treatment courses) of the drug SIRTURO® (bedaquiline) over a 4 year period through USAID’s programs for the treatment of drug-resistant TB. The drug donation will enable nearly 100 low- and middle-income eligible countries to access the life-saving drug for free under certain conditions.
Comments are closed.